Sapan Shah

Sapan Shah is the Chief Executive Officer of StrideBio, a gene therapy company dedicated to creating innovative genetic medicines for patients with rare and devastating conditions. With a background in pharmaceuticals and biotechnology, Sapan has a track record of driving novel therapies to address unmet medical needs. Previously, he led ARMGO Pharma, focusing on treatments for cardiac and rare muscle diseases. He also played a pivotal role in expanding Shionogi Inc.'s US pharmaceutical business, overseeing significant growth in sales and employees. Sapan is known for his successful joint-venture initiatives and co-founding Ezose Sciences, a pioneering glycomics company. His career began at McKinsey & Company, where he advised clients on R&D, commercial, and strategy matters.